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The reactions of four cymene-capped ruthenium(II) compounds with pro-apaptotic protein, 
cytochrome c (Cyt), and anti-proliferating protein lysozyme (Ly) in carbonate buffer were 
investigated by ESI-MS, UV–Vis absorption and CD spectroscopy. The complexes with two 
chloride ligands (C2 and C3) were more reactive toward proteins than those with only one (C1 
and C4), and the complex with S,N-chelating ligand (C4) was less reactive than one with O,N-
chelating ligand (C1). Dehalogenated complexes are most likely species initially coordinating 
proteins for all tested complexes. During the time, protein adducts vividly exchanged non-arene 
organic ligand L with CO3
2- and OH-, while cymene moiety was retained. In water, only 
dehalogenated adducts were identified suggesting that in vivo, in the presence of various anions, 
dynamic ligand exchange could generate different intermediate protein species. Although all 
complexes reduced Cyt, the reduction was not dependent on their reactivity to protein, implying 
that initially noncovalent binding to Cyt occures, causing its reduction, followed by coordination 
to protein. Cyt reduction was accompanied with rupture of ferro-Met 80 and occupation of this 
hem coordination site by a histidine His-33/26. Therefore, in Cyt with C2 and C3 less intensive 
reduction of hem iron leave more unoccupied target residues for Ru coordination, leading to 
more efficient formation of covalent adducts, in comparison to C1 and C4. This study contribute 
to development of new protein-targeted Ru(II) cymene complexes, and to design of new cancer 
therapies based on targeted delivery of Ru(II) arene complexes bound on pro-apoptotic/anti-
proliferating proteins as vehicles.  
 
Key words: Ruthenium(II)-cymene complexes; Protein metalation; Anticancer metallodrugs; 
Mass spectrometry. 
1. Introduction 
Cis platin and the 2nd and 3rd generation analogues, carboplatin and oxaliplatin, are widely used 
for treatment of testicular, ovarian, lung, head and neck, as well as colorectal cancer [1, 2]. 
However, inherent limitations, such as toxicity to normal cells causing severe side effects and 
acquired drug resistance, restrict their further wider applications [3]. Therefore, many other 
transition metal complexes with potential anticancer activity have been developed, with the clear 
aim to improve pharmacological properties [4]. Ruthenium complexes were identified as one of 
the alternate classes, due to kinetics of ligand substitution that is similar to platinum complexes, 
structural diversity and iron mimicking property. In the same time, they demonstrate lower 
toxicity, good selectivity for tumors, inhibition of the antimetastatic progression and 
antiangiogenic properties which make them very interesting for drug development. 
Ru(III) complexes NAMI-A, ([ImH][transRuCl4(DMSO)Im]) and KP1019, [InH][trans-
RuCl4In2] successfully completed phase I of clinical trials. Although NAMI-A is the only 
ruthenium compound to have reached the phase II stage [5], recently it has been withdrawn due 
to its toxicity profile and the lack of convincing preliminary efficacy results [6, 7]. It is believed 
that these ruthenium(III) complexes might be reduced to ruthenium(II) to exert their anticancer 
effect. With regard to this, a series of the half-sandwich ruthenium(II) based organometallic 
complexes ([(η6- arene)Ru(en)(Cl)]PF6, en = ethylenediamine, arene = benzene, pcymene (1), 
biphenyl (2), tetrahydroanthrance, etc.) have been developed and show promising cytotoxicity 
both in vitro and in vivo, and even cytotoxicity towards cisplatin-resistant cancer cell lines [8-
11]. As for cisplatin, DNA is a potential target for the Ru(II) arene complexes, most of which 
bind selectively to N7 of guanine [12-15]. However, it has been proposed that proteins could 
play more important roles in the action of ruthenium drugs than in that of platinum drugs [16]. 
One of the mode of action, that is proposed for ruthenium-based compounds, is via protein 
targets involved in cellular signaling pathways and the histone proteins of nucleosome core 
particles [17]. 
 As proteins are the first potential binding targets for the complexes in the bloodstream after their 
intravenous administration, interactions of anticancer therapeutics with proteins are very 
important to be investigated with aim to elucidate their pharmacokinetic pathways. Several 
studies investigated the reactivity of organoruthenium compounds towards peptides, like 
glutathione [1918, 2019], and proteins [20, 21, 22], like human serum albumin [21] human 
transferrin [22]. For instance, the RAPTA complexes exhibit a high affinity for protein 
molecules, favored over DNA binding due to the presence of the hydrophobic arene moiety. In 
addition, mass spectrometric-based assays reveal that these protein interactions are quite 
selective, identifying His33 as the preferred binding site in cytochrome c [23].  Analogous 
studies on other ruthenium-containing complexes, e.g. NAMI-A, implied the same conclusion, 
and histidine residue have also been shown to be important binding sites for KP1019 [24, 25].  
Above all, proteins have a crucial role in the transport of metal based drugs, their mode of action, 
as well as their overall pharmacological and toxicological profiles [26]. All these findings imply 
how important is to study metal based drugs protein interaction on the route toward discovering 
of new drug. To this aim a number of analytical techniques, as well as spectroscopic and 
biophysical methods, are extensively applied to study the reactivity of metal complexes with 
different biomolecules. The most advanced approach includes characterization of protein adducts 
of ruthenium anticancer drugs by X-ray crystallography [27-30], as well as molecular by mass 
spectrometry that has emerged in the last decade as a major tool to characterize the interactions 
of metallodrugs at a molecular level [27 31-3035], as well as by combined use of mass 
spectrometry and X-ray crystallography [36, 37]. 
For many cancers current chemotherapies alone are not efficient, requiring alternative 
therapeutic approaches, and one of the strategies is the exploitation of the proliferation and 
apoptosis pathways. Therefore, in the last few years pro-apoptotic and anti-proliferating proteins, 
and their targeted delivery to cancer cells, are gaining importance in cancer therapy. Cytochrome 
c is known as pro-apoptotic factor, triggering apoptosome assembly and caspase cascade that 
eventually lead to cell death. Delivering cytochrome c into the cytoplasm activates apoptosis 
downstream from many events, and avoidance of apoptosis is a hallmark of cancer.  Moreover, 
cytochrome c significantly increased the levels of apoptosis when combined with clinically used 
anticancer agents [3138]. On the other hand, lysozyme inhibits invasion and migration of cancer 
cells [3239], showing an anti-proliferative action against many cancer cell lines [3340]. Due to 
its ability to enhance the efficacy of chemotherapy treatments, lysozyme is becoming a 
promising co-adjuvant for anti-cancer therapies [3441]. 
With the aim to study cytotoxic potential of ruthenium complexes, a series of the half-sandwich 
ruthenium(II)-cymene complexes, have been developed earlier,  C1, [(6-p-cymene)RuL1Cl] 
[3542],  C2,  [(6-p-cymene)RuL2Cl2], C3, [(
6-p-cymene)RuL3Cl2] [3643] and C4, [(
6-p-
cymene)RuL4Cl] [3744], where L1 is isoquinoline-3-carboxylic acid,  L2 is N’-(1-(pyridin-4-
yl)ethyliden) octanehydrazide, L3 is N’-(1-(pyridin-3-yl)ethylidene) hydrazinecarbothioamide 
and L4 1-(7-chloroquinolin-4-yl) thiourea (Fig 1.). These complexes showed promising in vitro 
cytotoxicity, even towards cisplatin-resistant cancer cell lines [3542-3744]. To understand a 
possible mechanism of action of such types of compounds via protein targets, and to investigate 
their potential as cancer therapeutics in complex with pro-apoptotic and anti-proliferating 
proteins, their interactions with horse heart cytochrome c (Cyt) and egg white lysozyme (Ly) 
were investigated as model proteins. These two proteins and are also common model system for 
investigation of interactions of proteins with metal-based anticancer compounds by mass 
spectrometry, due to their low molecular mass [3138]. The interactions were monitored through 
ESI MS, UV–VIS absorption and CD spectroscopy, where speciation of protein adducts in water 
solution, with and without other anions (i.e. bicarbonate buffer), was followed, and the 
complexes differing in mode of ligand coordination and number of chloride anions were 
compared. 
 
2. Materials and methods 
2.1. Materials 
The horse heart cytochrome c was obtained from Sigma (C7752, St. Louis, MO, USA). The 
chicken egg white lysozyme was isolated and purified from fresh egg white according to a 
previously published method [3945] and protein purity was assessed by electrophoresis. C1 was 
prepared according to [3542], C2 and C3 as described in [3643], and C4 following previously 
published procedure [3744]. The deionized water used in the experiments was purified by a 
Milli-Q system (Millipore, Molsheim, France). 
2.2. Spectrophotometric and circular dichroism spectra measurements    
The interaction of horse heart cytochrome c (10 μM) with the ruthenium complexes (30 µM), 
was monitored in 20 mM ammonium hydrogen carbonate pH 7.4 at 37 °C, at different time 
intervals over a period of 48 h under aerobic conditions and the samples were kept in the dark. 
UV VIS spectra were recorded on NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, 
USA). 
CD spectra were recorded on a JASCO J-815 spectropolarimeter (JASCO, Tokyo, Japan) with 
protein concentration of 25 μM, with the ruthenium/protein molar ratio of 3:1 ratio, in 20 mM 
ammonium hydrogen carbonate pH 7.4 at 25 °C. The spectra were recorded in the range 300-600 
nm using 1.0 cm cuvettes. Each spectrum was acquired four times, and the results were 
averaged.  
2.3. ESI–MS analysis 
The samples were prepared in 20 mM ammonium hydrogen carbonate pH 7.4, with a protein 
concentration of 100 μM, and a ruthenium to protein molar ratio of 3:1. The stock solutions of 
ruthenium complexes were made in methanol, and in final reaction mixture with protein 
methanol was 4 % (v/v). The reaction mixtures were incubated for 24 and 48 h at 37 °C. The 
samples were extensively ultrafiltered and diluted with MilliQ water 10-fold for Cyt and 20-fold 
for Ly samples. After the samples were injected directly with flow 10 μL/min ESI–MS spectra 
were recorded by LTQ Orbitrap XL (Thermo Fisher Scientific Inc., USA) mass spectrometer, 
equipped with a conventional ESI source. The ionization was done in positive mode on heated 
electrospray ionization (HESI) probe. HESI parameters were: capillary temperature 275 oC, 
source voltage 4.2 kV, capillary voltage 42 V, tube lens voltage 120 V, vaporizer temperature 50 
oC, sheath, sweep and auxiliary gas flow rate was set at 15, 0 and 4 (arbitrary units), respectively. 
Acquisition was 5 minute per sample. MS spectra were acquired between m/z 100 and m/z 2000. 
For spectra acquisition a nominal resolution (at m/z 400) of 60000 was used. The ESI-MS data 




3. Results  
3.1. Interactions of Ru(II)-cymene complexes with lysozyme and  cytochrome c 
monitored by ESI-MS spectroscopy 
In this study we have monitored interactions of Ru(II) complexes with the proteins in carbonate 
buffer in order to get more realistic picture, having in mind that carbonate/bicarbonate is 
obligatory intracellular and extracellular ion present at concentration of about 25 mM. High-
resolution LTQ-Orbitrap ESI MS was used to monitor the adducts formed between four 
ruthenium complexes and proteins, Ly and Cyt. Representative deconvoluted ESI-MS spectra of 
Ly and Cyt incubated with C2, together with the spectra of the untreated proteins, are presented 
in Fig. 2 and Fig. 3, respectively.  The mass spectra of Ly and Cyt incubated with C1, C2, C3 
and C4 are shown in Figs. S1-S18. The major identified adducts of metal complexes with 
proteins are given in Table 1, and possible minor adducts are presented in Table S1. In addition, 
the relative intensity of unmodified and modified proteins was used to roughly estimate extent of 
protein modification by tested ruthenium complexes (Table S2).  
The molecular mass of untreated Ly (Fig. 2) was 14304.9638 Da, while the mass of untreated 
Cyt (Fig. 3) was 12358.3970 Da. The mass spectra of both proteins incubated for 24 h and 48 h 
with all tested ruthenium complexes show additional peaks in mass region 14550-14850 Da for 
Ly (Fig. 2B and C, S2-S10) and 12550-13000 Da for Cyt (Fig. 3B and C, S11-S18). 
C1 have similar reactivity with Ly and Cyt, resulting in several adducts with similar ESI MS 
peak pattern (Figs S2, S6, S11 and S15). The most dominant adduct of C1 with both Ly and Cyt 
is [RuCymL] (Table 1). In the group of possible minor adducts, the ligands are replaced with 
CO3
2- and OH-, and several minor adducts are represented as series of consecutive peaks 
differing in mass for one OH- ligand (Table S1, Figs. S2, S6, S11 and S15). In the case of both 
proteins, bound ligands are relatively stable, reflecting in almost the same peak pattern at both 24 
h and 48 h (Figs. S2, S6, S11 and S15), suggesting that after initial formation of adducts with C1 
further ligand exchange almost does not occur. 
According to the relative intensity of adducts, C2 and C3 have markedly higher reactivity to Cyt 
in comparison to Ly, and in comparison to C1. There are three different main adducts of C2 and 
C3 with Ly, [RuCym], [RuCym(CO3)],  and diruthenated adduct with [RuCym(CO3)] and Ru 
metal cation (Table 1). With Cyt only [RuCym] adduct dominates. Here, adduct with retained 
both cymen and ligand L, i.e. with [RuCymL], was detected only as minor adduct and mostly 
with C3. In the group of minor adducts ligand exchange for CO3
2- and OH- also took place. The 
adduct profiles and intensity of Ly are the same for C2 and C3 and do not change with time, 
suggesting that C2 and C3 have similar propensity and the rate of ligand exchange (Figs. S3 and 
S4), and that they are formed within 24 h and remain stable for 48 h (Figs. S3, S4, S7 and S8). 
Cyt adducts profiles and intensity are similar for C2 and C3, analogously to Ly (Figs. S12 and 
S13). However, adducts profile of Cyt change with time, including formation of new, as well as 
adducts with concomitant increase in modification extent (Figs. S12, S13, S16 and S17), 
implying that dynamic ligand exchange takes place after initial formation of adducts. For C3 
considerable quantity of new minor adducts are formed, even at some expense of decrease in the 
major adduct [RuCym] (Tables 1 and S1), indicating even more vivid ligand exchange between 
24 and 48 h of incubation. It is evident that Cyt is noticeably more prone to modification by C2 
and C3 than Ly, and that modification extent increase with the time (Table S2), but in modified 
Cyt species ligand exchange continuously takes place, implying possible subtle conformational 
changes of this protein in the presence of C2 and C3.  
C4 demonstrated the least reactivity toward investigated proteins. The most dominant adducts 
with Ly were [RuCym], [RuCym(CO3)], and one diruthenated adduct with [RuCym(CO3)] and 
Ru cation, while with Cyt, [RuCym] and [RuCymL] adducts are the major ones (Table 1).  Only 
the traces of Ly adducts are present after 24 h, and after 48 h extent of modification rises to the 
level reached by other complexes, on account of increase in the intensity of three initially formed 
adducts (Figs. S5 and S9). This suggests that binding of C4 to Ly is kinetically less favored than 
binding of other three complexes. The adducts profile of Cyt does not change with time 
significantly, but [RuCymL] adduct almost disappears and several minor adducts increase (Figs. 
S14 and S18), resulting in slight total increase in modification extent. This also pointed to the 
slow reactivity of C4 to Cyt, as the signal intensity of initially formed adducts increase with the 
time without formation of new adducts, implying that dynamic ligand exchange takes place after 
initial formation of adducts. 
In both proteins, [RuCymL] adducts were detected as major adduct with C1 at both time periods, 
and with C4 after 24 h, while they could be detected only as minor adduct with C2 and C3. This 
indicates that [RuCymL] is most likely species initially coordinating the protein for all tested 
complexes. However, in C1 ligand L remains during the time due to almost absence of ligand 
exchange, while for C4, and especially for C2 and C3, due to the vivid ligand exchange with 
CO3
2- and OH-, [RuCymL] adduct is transformed into carbonato/hydroxo complexes. This also 
suggests that ligand exchange dynamics of protein-bound complexes is C2, C3>C4>C1.  
In the most of studies, investigating interaction of Ru complexes with proteins by ESI-MS, the 
reaction mixtures were prepared in water [2831, 4046-4551], consequently not taking into 
account possible effects of biological anions on these interactions. Therefore, in order to 
compare interactions of Cyt with C3 and C4 in water with those in carbonate buffer, ESI-MS 
spectra of Cyt incubated with C3 and C4 for 48 h were recorded (Fig. S19-S21, Table S4). In 
contrast to the samples incubated in carbonate buffer, only [RuCym] adducts of Cyt were 
identified, suggesting that in vivo, in the presence of various anions, such as carbonate, 
phosphate, sulphate and a series of organic acids anions, dynamic ligand exchange could be 
expected generating different intermediate protein species.  
 
3.2. Interactions of Ru(II)-cymene complexes with cytochrome c monitored by UV-Vis 
absorption spectroscopy  
In order to get better insight into interactions of Cyt with Ru(II)-cymene complexes, UV-Vis 
spectra of Cyt, after 24 h and 48 h of incubation in the presence and in the absence of C1, C2, 
C3 and C4, were monitored (Figs. 4, S22-S30). After 24 h in the visible region of unmodified 
Cyt, two absorbance peaks of at 530 nm and 410 nm can be observed, typical for this protein in 
its oxidized form (Fe3+). Upon addition of ruthenium complexes, the appearance of peak at 550 
nm, along with shift of peak from 530 to 521 nm, indicates partial reduction of heme iron, even 
under aerobic conditions. In comparison to C2 and C3, the presence of C1 resulted in higher 
heme iron reduction, and C4 induced iron reduction to dramatic extent. After 48 h unmodified 
Cyt was slightly reduced, probably due to some photoreduction during spectra recording, as 
oxygen concentration was lower after 48 h than after 6 h or 24 h incubation. However, all tested 
complexes resulted in pronounced hem reduction after 48 h, with the most dramatic one induced 
by C4. C1, C2 and C3 induce progressive hem reduction during the 48 h, while heme reduction 
by C4 reached its maximum already after 6 h.  
3.3. Interactions of Ru(II)-cymene complexes with cytochrome c monitored by CD 
spectroscopy 
The CD spectra of the heme group in Cyt can be used to monitor the changes in its state, as well 
as the changes in tertiary structure around the heme moiety [4652]. Therefore, CD spectra of 
Cyt-ruthenium complexes adducts were recorded in Soret region (Figs. 5 and S31). Due to a 
Cotton effect, CD spectrum of native ferric Cyt in the Soret region has a bisignate band shape, 
with the positive band at 406 nm and the negative band at 416 nm, assigned to interactions 
between heme and the polypeptide backbone of the heme crevice. The interaction of all tested 
complexes with Cyt has resulted in decrease in positive CD signal at 406 nm, and the increase in 
negative signal at 416 nm, with appearance of signal at 425 nm. The decrease of maximum at 
406 nm with generation of peak at 425 nm is characteristic of ferrocytochrome [4652], 
suggesting that all complexes reduced heme iron to some extent. The most pronounced effect 
was observed after incubation with C1 after 24 h. After 48 h of incubation the extent of iron 
reduction did not change for C1, C2 and C3, while C4 caused dramatic reduction of iron 
between 24 and 48 h of incubation, with remarkable decrease of maximum at 406 nm, increase in 
generated peak at 425 nm and increase in minimum at 416 nm. The decrease and red shift in 406 
nm maximum and the increase in 416 nm minimum was also noticed due to of interaction of 
trans-indazolium(bisindazole)tetrachlororuthenate(III) with Cyt [4753].  
In the native state of ferrous Cyt, heme iron is ligated by His18 and Met80. The forms of Cyt,  
known to have the hem iron-Met80 coordination bond disrupted, lack of the 416 nm dichroic 
band, and therefore 416 nm band is the evidence for the axial bond between heme iron and 
Met80 [4854]. Similarly, the intensity of peak at 416 nm decreases with Cyt unfolding and the 
loss of integrity of the heme crevice [4652]. According to this, decrease in intensity of signal at 
416 nm due to binding of tested complexes, especially dramatic in the case of C4 after 48 h of 
incubation, suggests that the portion of Cyt molecules have changed heme crevice with disrupted 
hem iron-Met 80 bond. 
 
4. Discussion  
Having in mind that the success of a chemotherapy drug is strictly connected to its effectiveness 
against tumor metastases rather than against the primary lesions [6], Ru complexes showing anti-
metastatic activity are promising chemotherapeutics. As Ru complexes having anti-metastatic 
activity mainly target proteins [4248], investigation their interactions with proteins are essential 
to figure out still unclear mechanisms of their action. 
In this study interactions of four half-sandwich ruthenium(II)-cymene complexes, C1, C2, C3 
and C4, with anti-proliferating protein  lysozyme and anti-apoptotic protein cytochrome c, as 
model proteins were investigated.  MS spectra demonstrated that all tested complexes formed 
covalent adducts with both proteins, and dehalogenated complexes were most likely species 
initially coordinating the proteins. However, during incubation time vivid ligand exchange of 
non-arene organic ligand L with CO3
2- and OH- occurred, resulting in transformation of protein-
bound dehalogenated complexes into carbonato/hydroxo complexes with retained cymene 
moiety. The complexes C2 and C3 have shown higher reactivity toward proteins, and ligand L 
exchange of their protein adducts was more dynamics, in comparison to C1 and C4 complexes.  
The differences in ligand exchange dynamics of protein-bound complexes and the efficiency of 
adduct formation is due to intrinsic differences in the ability of tested complexes to release their 
leaving groups and react with protein side chains. C2 and C3 are complexes containing ligands 
coordinated in a monodentate manner and two Cl- ligands, that can be readily substituted by 
H2O/OH
-, and therefore capable to more efficiently react with proteins (Fig. 1). However, C1 has 
shown to be slightly more reactive to proteins than C4. This can be explained by O,N-chelated 
bidentate ligand in C1 and S,N-chelated bidentate ligand in C4. It was reported that Ru(II)-
cymene complexes, bearing pyronato and pyridonato (O,O-chelating) ligands, reacted readily 
with the model protein ubiquitin, in contrast to complexes with thiopyronato (S,O-chelating) 
ligand, which reacted only to a minor degree [4248].  
The chloride ligands are lost due to rapid aquation of all tested complexes in aqueous solutions 
[8], while cymene moiety is retained in all adducts with both protein. This is in accordance to 
literature data reporting the maintenance of arene moiety in protein adducts of arene-Ru(II) 
complexes, with arene stabilizing metal center and preventing rapid oxidation of the Ru(II) to 
Ru(III) [4955]. The fraction of adducts of all complexes contain bis-ruthenium adducts, 
indicating the existence of several available Ru binding sites on both proteins. The most of minor 
adducts of all tested complexes contain coordinated bicarbonate ion, also observed upon binding 
of RAPTA-T to transferrin in bicarbonate buffer [5056]. The series of minor adducts of all 
investigated complexes, with different number of coordinated HCO3
2- and OH- are formed by 
decarboxylation of bicarbonato complex to its hydroxo form. It should be mentioned that the 
complex can be in carbonato form, or it can protonate to its bicarbonate form, depending on the 
pH and the pKb for the protonation of the bound carbonato ligand. It seems that, similarly to 
platinum anticancer drugs, tested Ru complexes behave according to multistage rocket model 
[6], where leaving ligands (Cl- and organic ligands L) dissociate along the pathway to the target, 
while supporting ligand (Cym) remains bound to the metal and thus could contribute to tune its 
action. 
Interestingly, our previous studies determined IC50 for cytotoxic effects toward HeLa and A549 
cell lines for C2 (85.38 and 90.67 uM) and C3 (87.43 and 87.82 uM) [3643] is higher than one 
of C1 (45.35 and 25.76 uM) [3542] and C4 (56.45 and 31.49 uM) [3744]. These results are in 
accordance to inverse correlation between cytotoxic potency of the Ru-cymene compounds and 
the extent of protein adduct formation observed by Meier et al. [4248].  The authors explained 
this phenomenon by the fact that extensive protein binding accounts for a possible deactivation 
pathway of RuII-type metallodrugs, while low protein binding implies high stability toward 
biological nucleophiles, resulting in an increased probability that the drug reaches target in its 
active form. It was demonstrated that RAPTA-C, containing one monodentate ligand and two 
chlorides, is mainly protein targeting complex with low cytotoxicity, while RAED C, containing 
bidentate ligand and one two chloride, is mainly DNA targeting complex with high cytotoxic 
potential [17]. According to observed higher reactivity to proteins observed in this study and 
lower cytotoxic activity of C2 and C3, in comparison to C1 and C4, in analogy to RAPTA-C 
and RAED C, it seems that  C2 and C3 are more protein targeting and C1 and C4 more DNA 
targeting. C1 is the only one of tested complexes which gave the same major adduct for both 
proteins and the adduct contained bonded ligand L, similarly to RAPTA-C [2831]. Also, all 
tested complexes have shown lower reactivity toward Ly compared to Cyt, as was revealed for 
RAPTA-C complex [2831]. 
The ruthenium(II) compounds show a high selectivity for cysteine, methionine and histidine. For 
RuII-ɳ6-(cymene) complexes, such as RAPTA-C, in Cyt, His33 is the major interaction site 
[2831], while  in Ly His15 side chain is the preferred binding site of RuII6-arene complexes, 
such as Ru2(
6-benzene)2Cl4 [5157, 5258] and Ru(II)(
6-p-cymene)Cl2(H2O) [27]. Therefore, 
the most likely sites of binding of complexes tested in this study are His15 in Ly and His33 in 
Cyt.  
All tested complexes induced heme iron reduction in Cyt. However, heme reduction was higher 
in the presence of C1, and especially C4, in comparison to C2 and C3 complexes. Observed iron 
reduction is in the accordance with spectrophotometric effects on Cyt produced by other 
ruthenium (II)-cymene compounds, such as RAPTA-C and carbo-RAPTA [2831] and NAMI-A 
[4046]. Recently, Tamasi et al. [5359] have also observed Cyt reduction by fac-[RuII(CO)3Cl2L] 
complexes, and  hypothesized that Cyt reduction is the consequence of ruthenium binding to a 
specific protein site, capable of modulating the redox properties of the heme center.  However, as 
C1 and C4 gave notably lower yield of adducts with Cyt in comparison to C2 and C3 (Table 1), 
prominent reducing activity of C1, and especially C4, is actually consequence of their non-
covalent interactions with protein. Indeed, in UV region presence of C4 induce notable blue shift 
of maximum from 280 nm to 275 nm, suggesting more polar environment around Tyr and Trp 
residues and supporting noncovalent interactions of C4 in the vicinity of Tyr/Trp residues. These 
results also suggest that Cyt reduction does not necessarily depend on coordinative binding of 
ruthenium to protein, and it seems that complexes initially bind to Cyt noncovalently, causing its 
reduction, following by coordination to protein. Although all tested complexes have ruthenium-
cymene scaffold, it is obvious that ligand L determines target sites on protein for noncovalent 
complex binding thus modulating possibility and extent of Cyt reduction. This implies that 
coordinative binding of tested complexes could be at different sites on protein. The 
semiquantitative analysis of the observed spectral changes at 550 nm have shown that about 70% 
of the heme iron(III) undergoes reduction to iron(II) already 6 h after incubation of Cyt with C4 
and remains stable until 48 h of incubation. Based on analyses of mass spectra, heme reduction 
was not accompanied by oxidation of protein amino acid residues. Casini et al. also observed Cyt 
reduction with NAMI-A (about 60 %) [4046] and RAPTA-C (about 30 %)  [2831]. Mechanism 
of Cyt reduction by Ru complexes still remains unclear. Casini et al. [4046] assumed that 
reduction is mediated by ruthenium binding to a specific protein-binding site significantly 
affecting the redox behavior of Cyt, but electron transfer (direct or indirect) from Ru center to 
heme Fe3+ could not be excluded. Although the reduction potentials of Fe3+/2+  in heme of Cyt 
(0.26 V vs.NHE) [5460] and free Ru3+/2+  (0.25 vs.NHE) are similar, within a complex Ru3+/2+ 
reduction potential is determined by ligand environment and coordination geometry, and electro-
chemical properties of Ru complexes can be tuned by variation of the ligands [5561]. In our four 
tested Ru complexes, different electronic net donation from the ligands L and chlorides to the 
metal center, probably result in different kinetics and thermodynamics of electron transfer from 
Ru2+ to heme Fe3+. Indeed, similar influence of similar ligand on Ru3+/2+ reduction potential in 
C2 and C3 can be observed in the extent of Cyt reduction in the presence of these complexes. 
The heme iron reduction in the presence of ruthenium complexes was also confirmed by CD 
spectra in the Soret region, with the most pronounced effect of C3 and C4 complexes. In 
addition, it seems that, due to ruthenium complexes binding, the portion of Cyt molecules have 
changed heme crevice with disrupted hem iron-Met 80 bond.  In the unfolded state of Cyt, the 
iron center is axially ligated by the imidazoles of two histidines, the native His18, and either 
His26 or His33, which replaces the native axial ligand, Met80 [5662]. Droghetti et al. [5763] 
identified folded, but nonnative states of ferrous Cyt species, in which the native Met 80 ligand is 
exchanged with a histidine (His33 or His26). Based on all this, noncovalent interactions of all 
tested complexes with Cyt resulted in some reduction of heme and slight tertiary structure 
change as consequence of the rupture of iron (II)-Met 80 and occupation of this coordination site 
by a histidine His33/26. According to Cyt unfolding mechanism [5864], heme ligand exchange 
occurs while the protein is still compact. Indeed, charge state distributions of the Cyt modified 
by tested complexes exhibit the same bell-shaped curve as corresponding native Cyt, with the 
same maximum at z=8+ (not shown), suggesting no significant change in tertiary structure, 
reflecting in absence of additional exposure of protonable groups to the solvent. Therefore, in C2 
and C3 less intensive reduction of heme iron leaves more unoccupied His33/26, which are the 
main targets for Ru coordination, leading to more efficient formation of covalent adducts in 
comparison to C1 and C4.  
Therefore, in the presence of C1 and C4 more intensive reduction of heme iron results in the 
higher extent of iron-Met80 bond disruption. Consequent higher level of Met 80 ligand exchange 
with His33/His26 blocks His, which is necessary for Ru coordination, leading to less efficient 
formation of covalent adducts, in comparison to the presence of C2 and C3.  
Cyt itself is recognized as promising potent and selective anticancer drug due to its as pro-
apoptotic action, and its targeted delivery to cancer cells, followed by its smart release into the 
cytoplasm, becomes in the focus these years. Targeted delivery of Cyt, resulting in effective 
apoptosis of cancer cells, was achieved by encapsulation into ferritin [5965] or polymer 
nanoparticles [6066, 6167], cross-linking with transferrin [6268], conjugation with lipid-
apolipoprotein nanoparticles [6369] and immobilization in silica nanoparticles [6470]. Therefore, 
Cyt derivatives of Ru(II) complexes tested in this study, especially C2 and C3, have potential as 
therapeutics for cancer treatment from two reasons. On one hand, the tested complexes could be 
targeted delivered to cancer cells in the form of Cyt derivatives, providing their higher selectivity 
and efficiency. On the other hand, by binding of tested complexes, Cyt could act as more 




In general, according to results of this study, it could be concluded that interactions of Ru(II) 
complexes with proteins, beside coordinative binding, include their noncovalent interactions and, 
in the case of heme-proteins like Cyt, heme reduction. In heme proteins, noncovalent binding, 
and consequent heme reduction, could determine protein reactivity toward Ru(II) complexes. 
This study demonstrates that the reactivity of Ru(II) cymene complexes depends on the number 
of aquation prone-chloride ligands,  and the complexes with O,N-chelated bidentate ligands are 
more reactive than one with  S,N-chelated ligands. Therefore, these results could serve as guide 
in further development of protein-targeted Ru(II) cymene complexes.   
The presence of other possible metal-binding ligands, like in extracellular or intracellular milieu, 
modulates these interactions by ligand exchange, resulting in series of different adducts. In the 
cells there are many strong metal binding ligands present in mM concentrations, including 
carbonate ions. Their ability for exchange, e.g. to bind and to leave, determinate the extent, as 
well as mechanism of the binding of ruthenium complexes to the target biomacromolecules. 
Therefore, in searching for Ru(II) complexes mechanism of  action, investigation of ligand 
exchange of Ru(II) complexes is important, not only to identify possible reactive Ru(II) species 
interacting with proteins, but also to monitor further destiny of their protein adducts in different 
biological compartments.  
Although the protein reactivity toward Ru(II) complexes is determined by protein structure and 
ligands in Ru(II) coordination sphere, this reactivity should be described from both kinetics and 
stability aspect. Interaction between proteins and Ru(II) complex can be thermodynamically 
favored, but also slow, allowing Ru(II) complex to reach and interact with its target, such as 
DNA or nuclear proteins. On the other hand, stability of formed protein adducts with Ru(II) 
complex determine whether it remains blocked with non-target protein, or become available to 
its targets.   
Besides, the obtained results open the possibility for design of new therapies for treating cancers, 
based on Ru(II) arene complexes bound on pro-apoptotic/anti-proliferating proteins as vehicles. 
Their targeted delivery to cancer cell cytoplasm would enable higher selectivity and efficiency of 
bound Ru(II) complexes, while bound Ru(II) complexes could enhance pro-apoptotic/anti-
proliferating effects of proteins.  
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Tables and Figures 
 
Table 1. The main adducts of C1, C2, C3 and C4 with Ly and Cyt identified by deconvoluted 
ESI MS spectra after incubation of complexes with proteins in 20 mM ammonium hydrogen 
carbonate pH 7.4 at 37 ºC for 24 h and 48 h. The relative peak intensity of adducts is in 















Ly 24 h 14711.9631 406.9911 [RuCymL]  14713.0241 -1.0610 1.76 
Ly 48 h 14711.9402 406.0023 [RuCymL]  14713.9900 -2.0498   1.12 
Cyt 24 h 12766.4166 406.9972 [RuCymL]  12767.4715 -1.0549 1.25 
Cyt 48 h 12766.4077 406.9986 [RuCymL]  12767.4612 -1.0535 1.61 
C2 
Ly  24 h 
14539.8905 233.9681 [RuCym]2+ 14541.9352 -2.0447 0.78 
14600.8940 294.9716 [RuCym(CO3)] 14601.9110 -1.0259 1.13 
14700.9435 395.0211 [RuCym(CO3)], Ru2+ 14703.8243 -2.8808 1.41 
Ly 48 h 
14538.8742 232.9384 [RuCym]2+ 14541.9486 -3.0744 0.73 
14599.8843 293.9485 [RuCym(CO3)] 14601.9334 -2.0490 1.03 
14700.9457 395.0099 [RuCym(CO3)], Ru2+ 14703.8377 -2.8920 1.65 
Cyt 24 h 12593.3846 233.9911 [RuCym]2+ 12595.4063 -2.0217 11.09 
Cyt 48 h 12593.4239 233.9813 [RuCym]2+ 12595.4554 -2.0315 10.93 
C3 
Ly 24 h 
14538.8795 233.9243 [RuCym]2+ 14540.9680 -2.0885 0.96 
14600.8935 295.9383 [RuCym(CO3)] 14600.9528 -0.0592 1.51 
14701.9495 396.9943 [RuCym(CO3)], Ru2+  14702.8571 -0.9076 1.57 
Ly 48 h 
14537.8845 231.9414 [RuCym]2+ 14541.9559 -4.0714 0.81 
14600.8907 294.9476 [RuCym(CO3)]  14601.9407 -1.0499 1.22 
14700.9495 395.0064 [RuCym(CO3)], Ru2+  14703.8450 -2.8955 1.82 
Cyt 24 h 12593.3969 233.9919 [RuCym]2+ 12595.4178 -2.0209 12.3 
Cyt 48 h 12594.4366 234.9794 [RuCym]2+  12595.4699 -1.0333 8.67 
C4 
Ly 24 h 
14538.8650 233.8980 [RuCym]2+ 14540.9798 -2.1148 0.19 
14599.8866 294.9196 [RuCym(CO3)] 14600.9646 -1.0779 0.14 
14699.9566 394.9896 [RuCym(CO3)], Ru2+  14702.8689 -2.9123 0.11 
14775.9108 470.9438 [RuCymL] 14777.9926 -2.0818 0.07 
14857.9089 552.9419 [RuCym(CO3)], 
[RuCym(OH)]1+ 
14853.9801 3.9288 0.07 
Ly 48 h 
14538.9392 233.9668 [RuCym]2+ 14540.9852 -2.0460 0.82 
14598.9395 293.9671 [RuCym(CO3)] 14600.9610 -2.0304 0.66 
14701.0202 396.0478 [RuCym(CO3)], Ru2+  14702.8743 -1.8541 1.68 
Cyt 24 h 
12593.3657 233.9538 [RuCym]2+ 12595.4247 -2.0590 1.01 
12830.3888 470.9769 [RuCymL]  12832.4375 -2.0487 0.61 











Figure 1. Structures of investigated complexes: (C1) [(η6 -p-cymene)RuL1Cl],  (C2) [(η6 -p-
cymene RuL2Cl2], (C3) [(η





Figure 2. (A) Deconvoluted ESI-MS spectra of Ly incubated for 24 h. Deconvoluted ESI-MS 
spectra of Ly incubated with C2 during 24 h (B) and 48 h (C). The samples were incubated in 20 
mM ammonium hydrogen carbonate pH 7.4 at 37 ºC. Inserts represent corresponding zoom out 
of mass region 14400-15400 Da  
 
 
Figure 3. (A) Deconvoluted ESI-MS spectra of Cyt incubated for 24 h. Deconvoluted ESI-MS 
spectra of Cyt incubated with C2 during 24 h (B) and 48 h (C). The samples were incubated in 
20 mM ammonium hydrogen carbonate pH 7.4 at 37 ºC. Inserts represent corresponding zoom 
out of mass region 12500-13500 Da 
 
Figure 4. Absorption UV–vis spectra of cytrochrome c in 20 mM ammonium hydrogen 
carbonate pH 7.4 before and after addition of C1, C2, C3 and C4. Spectra were recorded at 37 
°C after 24 h (A) and after 48 h (B). Insets show the spectra more in detail (region 450-600 nm).  
 
Figure 5. The effect of Ru(II) complexes on the Soret CD intensity of Cyt. Cyt and Cyt  
incubated with C1, C2, C3 and C4 were incubated in 20 mM ammonium hydrogen carbonate pH 
7.4 for 24 h (A) and 48 h (B) at 37 °C at the molar ratio Ru(II)/Cyt  = 3:1, Cyt = 100 uM.  
